Vol. 5 No. 3 (2025)
Reimbursement Reviews

Enfortumab Vedotin (Padcev)

decorative image of the issue cover

Published March 24, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses enfortumab vedotin (Padcev), 10 mg per mL (single-dose vials containing 20 mg and 30 mg of enfortumab vedotin), lyophilized powder for solution for IV infusion.
  • Indication: In combination with pembrolizumab, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer with no prior systemic therapy for metastatic urothelial cancer.